The global clinical trials activity saw an increase of 5.9% in Q2 2021, when compared with the rolling average of the last four quarters (Q2 2020 to Q1 2021), according to GlobalData.
Of the overall activity, industry sponsored trials accounted for a 51.6% share in Q2 2021, marking an increase of 2.0% in the total share when compared with the four-quarter average.
Go deeper with GlobalData
Non-industry sponsored trials accounted for a 48.4% share of all the clinical trials globally in Q2 2021, marking a decrease of 2.0% in the overall share when compared with the four-quarter average.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top therapy areas for industry and non-industry sponsored clinical trials in Q2 2021
Oncology was the leading therapy area for industry sponsored clinical trials in Q2 2021, accounting for a 30.9% share of all trials.
This was followed by the following therapy areas: Infectious Disease with a 17.6% share, Central Nervous System with a 12.9% share, Cardiovascular with a 7.3% share and Metabolic Disorders with a 7.0% share.
In the last four quarters, Oncology held a lead over other therapy areas for industry sponsored clinical trials with a 26.6% share, followed by Infectious Disease with a 21.5% share, Central Nervous System with a 13.1% share, Metabolic Disorders with a 7.8% share, and Cardiovascular with a 7.3% share.
| Industry sponsored trials activity: 4-Quarter Avg. vs Q2 2021 | |||
|---|---|---|---|
| Therapy Area | 4-Quarter Avg. | Q2 2021 | Activity |
| Oncology | 26.6% | 30.9% |  |
| Infectious Disease | 21.5% | 17.6% |  |
| Central Nervous System | 13.1% | 12.9% | |
| Cardiovascular | 7.3% | 7.3% | |
| Metabolic Disorders | 7.8% | 7.0% | |
| Gastrointestinal | 6.0% | 5.6% | |
| Immunology | 5.1% | 5.0% | |
| Respiratory | 7.0% | 4.2% | |
| Dermatology | 4.2% | 3.9% | |
| Musculoskeletal Disorders | 3.7% | 3.4% | |
| Ophthalmology | 2.9% | 2.9% | |
| Hematological Disorders | 2.8% | 2.7% | |
| Genito Urinary System And Sex Hormones | 2.6% | 2.5% | |
| Women’s Health | 1.6% | 1.9% | |
| Genetic Disorders | 1.5% | 1.7% | |
| Ear Nose Throat Disorders | 1.3% | 0.8% | |
| Mouth and Dental Disorders | 0.5% | 0.6% | |
| Male Health | 0.9% | 0.5% | |
| Hormonal Disorders | 0.5% | 0.4% | |
| Nutritional Disorders | 0.4% | 0.3% | |
| Non Malignant Disorders | 0.2% | 0.1% | |
Oncology was the leading therapy area for non-industry sponsored clinical trials in Q2 2021, accounting for a 26.2% share of all trials.
This was followed by the following therapy areas: Central Nervous System with a 24.0% share, Infectious Disease with a 17.5% share, Cardiovascular with a 9.7% share, and Gastrointestinal with a 5.5% share.
In the last four quarters, Oncology System held a lead over others for non-industry sponsored clinical trials with an average share of 24.3%, followed by Infectious Disease with a 22.6% share, Central Nervous System with a 21.3% share, Cardiovascular with a 9.1% share, and Gastrointestinal with a 5.7% share.
| Non-Industry sponsored trials activity: 4-Quarter Avg. vs Q2 2021 | |||
|---|---|---|---|
| Therapy Area | 4-Quarter Avg. | Q2 2021 | Activity |
| Oncology | 24.3% | 26.2% | |
| Central Nervous System | 21.3% | 24.0% | |
| Infectious Disease | 22.6% | 17.5% | |
| Cardiovascular | 9.1% | 9.7% | |
| Gastrointestinal | 5.7% | 5.5% | |
| Metabolic Disorders | 4.5% | 5.5% | |
| Musculoskeletal Disorders | 4.2% | 4.4% | |
| Respiratory | 5.7% | 4.1% | |
| Immunology | 2.9% | 3.3% | |
| Women’s Health | 3.9% | 2.8% | |
| Genito Urinary System And Sex Hormones | 2.6% | 2.7% | |
| Hematological Disorders | 2.7% | 2.2% | |
| Dermatology | 2.1% | 2.1% | |
| Ophthalmology | 1.4% | 2.1% | |
| Mouth and Dental Disorders | 1.8% | 1.5% | |
| Hormonal Disorders | 0.6% | 0.9% | |
| Nutritional Disorders | 0.6% | 0.9% | |
| Ear Nose Throat Disorders | 0.9% | 0.8% | |
| Genetic Disorders | 0.6% | 0.6% | |
| Male Health | 0.5% | 0.3% | |
| Non Malignant Disorders | 0.4% | 0.3% | |
Top regions in industry and non-industry sponsored clinical trials activity in Q2 2021
Asia-Pacific held the top position for industry sponsored clinical trials activity in Q2 2021 with a 48.0% share, compared to 53.6% in the last four quarters.
North America stood at second place with a 37.3% share in Q2 2021, over 31.9% in the last four quarters, followed by Europe with a 30.0% share in Q2 2021, as against 27.7% in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Single country studies held an 82.2% share in industry sponsored clinical trials in Q2 2021 when compared with 84.2% of the average recorded in the last four quarters. Multinational trials accounted for a 17.8% share in Q2 2021, as against the four-quarter average of 15.8%.
Asia-Pacific region held the top position in non-industry sponsored clinical trial activity in Q2 2021 with a 48.1% share, over 46.5% in the last four quarters.
North America held the second position with a 22.5% share in Q2 2021, over 18.6% in the last four quarters, followed by Europe with an 18.7% share in Q2 2021, as against 15.9% in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Single country studies held a 98.7% share for non-industry sponsored clinical trials in Q2 2021, compared to 98.6% in the last four quarters. Multinational trials accounted for a 1.3% share in Q2 2021, as against 1.4% in the last four quarters.
Industry and non-industry sponsored clinical trials by Phase in Q2 2021
Phase II trials outnumbered all other studies with a 41.1% share for industry sponsored trials in Q2 2021, compared to 34.9% average in the last four quarters.
The share of Phase I trials stood at 28.5% in Q2 2021, as against the four-quarter average of 36.8%. Phase III trials held an 18.3% share in Q2 2021, registering an increase of 1.4% over the last four quarters average, followed by Phase IV trials with a 12.1% share in Q2 2021, as against the four-quarter average of 11.4%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Phase II trials outnumbered all other trials with a 47.7% share for non-industry sponsored clinical trials in Q2 2021, compared to 45.0% in the last four quarters.
Phase IV trials stood at second place with a 21.3% share in Q2 2021, compared to 20.0% in the last four quarters. Phase III trials held a 16.6% share in Q2 2021, as against 19.7% in the last four quarters, followed by Phase I trials with a 14.4% share in Q2 2021 over 15.2% average recorded in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
